HLA class I expression in bladder carcinomas.
HLA class I molecules are frequently lost in a large variety of human carcinomas, possibly because of T-cell immune selection of major histocompatibility complex class I deficient tumor variants. We report that this phenomenon is also a frequent event in bladder carcinomas. Of a total of 72 bladder carcinomas, 72% of the tumors had at least one alteration in HLA class I expression. These altered HLA class I phenotypes were classified as total HLA class I loss (25%; phenotype I); HLA-A or/and HLA-B locus-specific loss (12%; phenotype III); and HLA class I allelic loss (35%; phenotype II or IV). Comparison of histopathological parameters with HLA class I expression showed a statistically significant relationship with the degree of differentiation and tumor recurrence.
Cabrera
T
T
Department of Clinical Analysis, Virgen de las Nieves University Hospital, University of Granada, Granada, Spain.
Pedrajas
G
G
Cozar
J M
JM
Garrido
A
A
Vicente
J
J
Tallada
M
M
Garrido
F
F
D002277:Carcinoma / Q000235:genetics / Q000276:immunology* / Q000473:pathology; D005805:Genes, MHC Class I; D006680:HLA Antigens / Q000235:genetics / Q000378:metabolism*; D015395:Histocompatibility Antigens Class I / Q000145:classification / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D001749:Urinary Bladder Neoplasms / Q000235:genetics / Q000276:immunology* / Q000473:pathology
D006680:HLA Antigens; D015395:Histocompatibility Antigens Class I